Literature DB >> 33656546

A dual immune signature of CD8+ T cells and MMP9 improves the survival of patients with hepatocellular carcinoma.

Huan Ding1, Huan Hu1, Feifei Tian1, Huaping Liang2.   

Abstract

The 5-year survival of hepatocellular carcinoma (HCC) is difficult due to the high recurrence rate and metastasis. Tumor infiltrating immune cells (TICs) and immune-related genes (IRGs) bring hope to improve survival and treatment of HCC patients. However, there are problems in predicting immune signatures and identifying novel therapeutic targets. In the study, the CIBERSORT algorithm was used to evaluate 22 immune cell infiltration patterns in gene expression omnibus (GEO) and the cancer genome atlas (TCGA) data. Eight immune cells were found to have significant infiltration differences between the tumor and normal groups. The CD8+ T cells immune signature was constructed by least absolute shrinkage and selection operator (LASSO) algorithm. The high infiltration level of CD8+ T cells could significantly improve survival of patients. The weighted gene co-expression network analysis (WGCNA) algorithm identified MMP9 was closely related to the overall survival of HCC patients. K-M survival and tROC analysis confirmed that MMP9 had an excellent prognostic prediction. Cox regression showed that a dual immune signature of CD8+ T cells and MMP9 was independent survival factor in HCC. Therefore, a dual prognostic immune signature could improve the survival of patient and may provide a new strategy for the immunotherapy of HCC.
© 2021 The Author(s).

Entities:  

Keywords:  CD8+ T Cells; Hepatocellular carcinoma; MMP9; WGCNA analysis; immune signature

Mesh:

Substances:

Year:  2021        PMID: 33656546      PMCID: PMC7969702          DOI: 10.1042/BSR20204219

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  41 in total

1.  The small-molecule inhibitor selectivity between IKKα and IKKβ kinases in NF-κB signaling pathway.

Authors:  Feifei Tian; Peng Zhou; Wenyuan Kang; Li Luo; Xia Fan; Jun Yan; Huaping Liang
Journal:  J Recept Signal Transduct Res       Date:  2014-11-11       Impact factor: 2.092

2.  Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.

Authors:  Monika Julia Wolf; Arlind Adili; Kira Piotrowitz; Zeinab Abdullah; Yannick Boege; Kerstin Stemmer; Marc Ringelhan; Nicole Simonavicius; Michèle Egger; Dirk Wohlleber; Anna Lorentzen; Claudia Einer; Sabine Schulz; Thomas Clavel; Ulrike Protzer; Christoph Thiele; Hans Zischka; Holger Moch; Matthias Tschöp; Alexei V Tumanov; Dirk Haller; Kristian Unger; Michael Karin; Manfred Kopf; Percy Knolle; Achim Weber; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

Review 3.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

4.  MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.

Authors:  S-J Sun; N Wang; Z-W Sun; J Chen; H-W Cui
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-08       Impact factor: 3.507

5.  The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Authors:  David Agdashian; Mei ElGindi; Changqing Xie; Milan Sandhu; Drew Pratt; David E Kleiner; William D Figg; Julie A Rytlewski; Catherine Sanders; Erik C Yusko; Bradford Wood; David Venzon; Gagandeep Brar; Austin G Duffy; Tim F Greten; Firouzeh Korangy
Journal:  Cancer Immunol Immunother       Date:  2019-01-28       Impact factor: 6.968

6.  Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.

Authors:  Feng Xu; Hongpan Zhang; Jiexin Chen; Ling Lin; Yongsong Chen
Journal:  Int Immunopharmacol       Date:  2019-12-10       Impact factor: 4.932

Review 7.  Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.

Authors:  T Mocan; Z Sparchez; R Craciun; C N Bora; D C Leucuta
Journal:  Clin Transl Oncol       Date:  2018-11-01       Impact factor: 3.405

8.  IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.

Authors:  Kazuyoshi Takeda; Masafumi Nakayama; Yoshihiro Hayakawa; Yuko Kojima; Hiroaki Ikeda; Naoko Imai; Kouetsu Ogasawara; Ko Okumura; David M Thomas; Mark J Smyth
Journal:  Nat Commun       Date:  2017-02-24       Impact factor: 14.919

Review 9.  Hepatocellular carcinoma treatment: hurdles, advances and prospects.

Authors:  Ratna Kumari; Manoj Kumar Sahu; Anindita Tripathy; Kanishka Uthansingh; Manas Behera
Journal:  Hepat Oncol       Date:  2018-09-28

10.  Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis.

Authors:  Mengzhou Guo; Feifei Yuan; Feng Qi; Jialei Sun; Qianwen Rao; Zhiying Zhao; Peixin Huang; Tingting Fang; Biwei Yang; Jinglin Xia
Journal:  J Transl Med       Date:  2020-08-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.